Barriers to using a nationwide skin cancer screening program: Findings from Germany (2018) Goerig T, Schneider S, Schilling L, Diehl K Journal article Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study (2018) Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, et al. Journal article Reliability of determining the resectability of locally progressed pancreatic ductal adenocarcinomas - results from the CONKO-007 multicenter randomized controlled trial (EudraCT:2009-014476-21) (2018) Wittel UA, Golcher H, Gruetzmann R, Bechstein WO, Belyaev O, Uhl W, Ghadimi M, et al. Conference contribution Radiosensitizing and radioprotecting effect of kinase-inhibitor Palbociclib in different normal tissue and cancer cell lines (2018) Jost T, Hecht M, Fietkau R, Distel L Conference contribution Pathologic complete response after induction therapy and surgery is an independed long-term survival prognostic factor in locally advanced non-small cell lung cancer (2018) Schreiner W, Dudek W, Lettmaier S, Rieker R, Fietkau R, Sirbu H Conference contribution Inflammatory cells infiltrating HPV positive and negative head and neck squamous cell carcinoma (2018) Distel L, Farhoumand D, Haderlein M, Fietkau R Conference contribution Effect of the kinase-inhibitor Palbociclib on radio-therapeutic treatment in a 3D cell culture model (2018) Jost T, Hecht M, Fietkau R, Distel L Conference contribution Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use (2018) Cao J, Wiesweg M, Fuchs M, Stein A, Karthaus M, Lettmaier S, Kretzschmar A, et al. Conference contribution 12x6Gy-the Erlangen stereotactic radiotherapy treatment concept result in 95% local progression-free survival for bronchial carcinoma and 83% for pulmonary metastases after 3 years (2018) Lubgan D, Rutzner S, Lambrecht U, Fietkau R Conference contribution RECREATE: Treatment reality for mRCCpatients following first line Pazopanib therapy - a retrospective chart review (2018) Hegele A, Von Der Heyde E, Goebell P, Huebner A, Zengerling F, Klier J, Belz H, et al. Conference contribution